2023 Mark Foundation Endeavor Award The Mark Foundation Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts. $3M / 3 years. LOI due July 13, 2022. Mark Foundation Non-Federal Basic Science Clinical Research Translational Research
NIH Director’s Pioneer Award Program (DP1-Clinical Trial Optional) RFA-RM-22-018. $700K/year (5 years). Application due 9/9/2022. The NIH Director’s Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation’s research workforce. Thus, individuals from all backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator’s research program or elsewhere. The NIH Director’s Pioneer Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. National Institutes of Health (NIH) Federal Basic Science Translational Research Clinical Research
Pediatric Immunotherapy Network (PIN) (U01-Clinical Trial Optional) RFA-CA-22-016. $450K/year (5 years). LOI due 8/27/2022. Application due 9/27/2022. Pre-application webinar on July 14, 2022 (pre-registration required). Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to solicit applications for the Pediatric Immunotherapy Network (PIN). The overall goal of this FOA is to establish a collaborative network consisting of investigators with relevant expertise to develop and advance novel translational immunotherapy approaches for children and adolescents with solid tumors including brain tumors. This FOA solicits U01 applications for discrete research projects that address relevant research opportunities focused on pediatric solid tumors (e.g., mechanisms of immune evasion, development of pre-clinical models, discovery and validation of novel therapeutic targets, development of novel pediatric immunotherapy agents and treatment approaches such as cancer vaccines, cellular therapy, and combinations with immunotherapy agents. Successful applicants will become members of the Pediatric Immunotherapy Network (PIN), which will address current challenges in pediatric cancer immunotherapy and accelerate the pace at which effective immunotherapies are realized for pediatric solid tumors. National Institutes of Health (NIH) Federal Basic Science Translational Research Clinical Research
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01-Clinical Trial Optional) PAR-22-131. Multiple deadlines. Earliest application due 10/5/2022. This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic information and/or meta data obtained from platforms including but not limited to lower resolution diagnostic acquisitions and systemic biomarker results to high resolution single-cell analytics / imaging applied to the characterization of heterogeneous cell populations within tumor for improving current approaches for: (1) the early detection of organ confined premetastatic aggressive cancer, and, (2) identifying precancerous lesions associated with the development of a subsequent lethal phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions by improving detection sensitivity and specificity of integrated multiparametric platforms. For example, N-dimensional co-registered, cross-correlated imaging data integrated with multiplexed biomarker results and/or digital pathomics, glycomics, or metabolomic imaging using analytic strategies such as artificial intelligence or virtual reality visualization techniques. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of potentially lethal cancer versus non-lethal disease, (2) minimize/better manage overdiagnosis and (3) reduce false positives and false negatives. National Institutes of Health (NIH) Federal Clinical Research Translational Research
FY22 Breast Cancer Research Program (BCRP) The DoD Congressionally Directed Medical Research Programs: FY22 BCRP is currently accepting applications for the Transformative Breast Cancer Consortium Award II. $25M/4 years. Preproposal due Aug 3, 2022. Department of Defense (DoD) Federal Translational Research Clinical Trials Allowed Clinical Research
2022 Gabrielle's Angel Foundation for Cancer Research Blood-related cancers. Limited submission (2 junior faculty invited to apply). Requires CFCCC review and selection. $225K/3 years. Internal deadline July 13, 2022. Gabrielle’s Angel Foundation Limited Funding Opportunity Early Career Translational Research Clinical Research
NCI Research Specialist (Laboratory-based Scientist) Award (R50-Clinical Trial Not Allowed) PAR-22-187. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These non-tenure track scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. It is anticipated that only exceptional scientists who want to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators, will be competitive for this award. Salary support and travel costs. Application due Nov 2, 2022 (LOI due 30 days prior). National Institutes of Health (NIH) Federal Basic Science Translational Research Clinical Research
NCI Research Specialist (Core-based Scientist) Award (R50 – Clinical Trial Not Allowed) PAR-22-188. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity. Salary support and travel costs. Application due Nov 2, 2022 (LOI due 30 days prior). National Institutes of Health (NIH) Federal Basic Science Translational Research Clinical Research